StreetAlpha.app
Home › Stocks › ONCY

Oncolytics Biotech Inc (ONCY)

Healthcare
$0.35
▼ −10.37%
LAST CLOSE · NOV 20

Oncolytics Biotech develops pelareorep, an experimental intravenous cancer therapy for gastrointestinal tumors. It last closed at $0.35 on Nov 20, down 10.37% on the day. Over the last 12 months ONCY insiders bought $363K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is ONCY in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ONCY.

Key Stats

Fiscal 2024
Results
Net income
−CAD 31.7M
Balance sheet
Cash & equivalents
CAD 15.9M
At Dec 31
Shareholder equity
CAD 6.0M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2020: −CAD 22.5M−CAD 22.5MFY2020FY2021: −CAD 26.3M−CAD 26.3MFY2021FY2022: −CAD 24.8M−CAD 24.8MFY2022FY2023: −CAD 27.8M−CAD 27.8MFY2023FY2024: −CAD 31.7M−CAD 31.7MFY2024

From ONCY's SEC filings, latest 10-Q for the period ending Dec 31, 2024 (filed Nov 13). Figures are in CAD. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
EPS and revenue estimates
Year-ago EPS
Same quarter last year
Options-implied move
Move priced in by options
Analyst consensus
Ratings from the last 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on ONCY: 0 upgrades, 0 downgrades, 0 initiations
HC WainwrightReiterated
Nov 21Buy 

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on ONCY
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ONCY

Technical Analysis

ONCY · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 17% below its 20 day and 53% below its 50 day average. It is 133% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 37), near oversold. The nearest support is the 52 week low at $0.33, and the nearest resistance the Pivot at $0.36.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNear oversold
VolatilityHigh, 14.4%/day
Key levels
$1.3052 week high+271.4%
$0.81200 day average+131.4%
$0.68100 day average+94.3%
$0.5450 day average+54.3%
$0.46Swing high (Nov 6)+31.4%
$0.4120 day average+17.1%
$0.38Pivot R1+8.6%
$0.36Pivot+2.9%
$0.35Last close
$0.3352 week low−5.7%
$0.33Pivot S1−5.7%
$0.33Swing low (Nov 17)−5.7%
Indicators
RSI (14)37.28Weak, oversold below 30Neutral
MACD-0.04Above its signal lineBullish
Stochastic47.2Middle of its rangeNeutral
ADX (14)35.8Trending down
Williams %R-86.9Oversold below −80, overbought above −20Oversold
CCI (20)-124.2Oversold below −100, overbought above 100Oversold
Rate of change−20.3%Change over 10 sessionsBearish
ATR (14)$0.05Typical daily range, 14.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ONCY

What happened before

See how ONCY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ONCY usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ONCY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ONCYHow many large options trades hit ONCY, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ONCY Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲29 buying vs 23 selling
  • ▼Held by funds -0.7 pts
  • ▲Funds holding +2
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding7775+2.7%
In funds' top 1000–
Held by funds2.4%3.1%−0.7 pts
New / increased10 / 1972 / 0−59.7%
Reduced / sold out14 / 91 / 1+1050.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ONCY institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ONCY Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$363K12 buys · 10 insiders
Sold$00 sales · 0 insiders
Cluster buy: 9 insiders bought $348K between Jan 16 and Feb 12.
2026-01 bought $104K2026-02 bought $244K2026-03 bought $15KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Mar 12Jared KellyCEOBuy5,050$0.96$5K
Mar 11James T. ParsonsDirectorBuy10,000$1.03$10K
Feb 12Jared KellyCEOBuy35,100$0.84$29K
Feb 12Bernd R. SeizingerDirectorBuy100,000$0.84$84K
Feb 12Patricia S AndrewsDirectorBuy35,400$0.86$30K
Feb 12Deborah Margaret BrownDirectorBuy25,000$0.85$21K
Every insider buy and sale for ONCY over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ONCY insider trades →

From SEC Form 4 filings by ONCY's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ONCY is in one of them and how their past ONCY trades turned out.

ONCY in the AI portfolios
Loading…

ONCY News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ONCY in an article yet. Here's the latest on the wider market.

ONCY in the news

About Oncolytics Biotech

Oncolytics Biotech is a biopharmaceutical company based in San Diego, California. It is developing pelareorep, an experimental cancer therapy given intravenously that is made from a common virus that does not cause disease. The company is testing pelareorep alone and with other cancer treatments, mainly for gastrointestinal cancers, and plans to partner with larger drug companies. Its intended customers are cancer patients and the doctors who treat them.

Headquarters
San Diego, CA
Founded
1998